The U.K. will start offering Eli Lilly’s (LLY) weight loss drug Mounjaro next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of treating obesity amid surging demand, STAT’s Andrew Joseph reports. The limited launch will come as the National Health Service tests a variety of new services to care for people living with obesity and is designed to ensure health care professionals can continue to meet the full range of health needs of all their patients, according to the report.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly CEO says he will fight for FDA , challenge Kennedy’s stance, NYT says
- Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG
- Eli Lilly’s (LLY) Zepbound Outperformed Novo Nordisk’s Wegovy in Study
- Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz
- Morning Movers: Salesforce jumps after Q3, Foot Locker sinks after guidance cut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
